The global cancer supportive care products market is witnessing substantial growth due to the increasing prevalence of cancer cases worldwide. These products aim to alleviate the adverse effects of cancer treatments and improve patients' quality of life. The rising demand for effective supportive care solutions, such as anti-emetics, pain management drugs, and growth factors, drives market expansion. Pharmaceutical companies are focusing on innovation to develop targeted therapies, provide better symptom management, and address the unmet needs of cancer patients, ensuring enhanced healthcare outcomes globally.
According to Data Bridge Market Research, the Global Cancer Supportive Care Products Market is expected to reach the value of USD 20,124.54 million in 2021 and is further estimated to reach USD 24,519.80 million by 2029, and is expected to grow at a CAGR of 2.5% during the forecast period of 2022 to 2029.
“Increasing of the aging population”
In cancer supportive care, geriatric co-management for cancer patients is successful. According to a retrospective cohort study published in August 2020 in JAMA Network Open titled "association of geriatric management and 90-Day postoperative mortality among Patients aged 75 years and Older with cancer," geriatric co-management was associated with significantly lower 90-day postoperative mortality among older cancer patients.
What restraints the growth of the global cancer supportive care products market?
" High treatment cost can impede the market growth”
Cancer treatment and supportive care products can be expensive, placing a substantial financial burden on patients. The costs of chemotherapy, radiation therapy, medications, and supportive care add up, making them inaccessible for some individuals, particularly those without adequate health insurance or financial resources. High treatment costs can lead to delayed or incomplete treatments, compromising patients' health outcomes. Access to affordable and comprehensive cancer care, including supportive care products, is essential to ensure equitable and effective cancer management for all patients.
Segmentation: Global Cancer Supportive Care Products Market
The global cancer supportive care products market is segmented on the basis of drug class, indication, and distribution channel.
- On the basis of drug class, the cancer supportive care products market is segmented into nonsteroidal anti- inflammatory drugs, anti-infective, anti-emetics, Monoclonal Antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, granulocyte colony stimulating factor.
- On the basis of indication, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukemia, ovary cancer, melanoma cancer, and others.
- On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies, and compounding pharmacies.
Regional Insights: North America dominates the Global Cancer Supportive Care Products Market
North America dominates the cancer supportive care products market because the U.S. is the home to many giant market players in the Cancer Supportive Care Products market.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the increasing demand for large USVs for commercial and defense applications such as combat operations, cargo transportation, and others in China.
To know more about the study, visit, https://www.databridgemarketresearch.com/fr/reports/global-cancer-supportive-care-products-market
Recent Developments in the Global Cancer Supportive Care Products Market
- In August 2020, in a late-stage study, Bristol Myers Squibb stated that Idhifa, which has been approved by the FDA for relapsed or refractory AML with an IDH2 mutation, failed to show efficacy in improving survival in the same patient population when given alongside optimum supportive treatment.
- In September 2020, Merck presented more than 30 abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
The Prominent Key Players Operating in the Global Cancer Supportive Care Products Market Include:
- Acacia Pharma Group Plc (Poland)
- Teva Pharmaceuticals Industries Ltd (Israel)
- Fagron Group (Poland)
- KYOWA HAKKO BIO CO., LTD. (Japan)
- APR (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
Above are the key players covered in the report, to know about more and exhaustive list of global cancer supportive care products market companies contact, https://www.databridgemarketresearch.com/fr/contact
Research Methodology: Global Cancer Supportive Care Products Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by dbmr research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
